Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks with high potential. In a report released on September 29, Leerink Partners maintained a Sell rating on Summit Therapeutics Inc. (NASDAQ:SMMT) without assigning a price target.
In addition, Barclays also maintained a Sell rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on September 25 with a $13 price target.
However, Asthika Goonewardene from Truist Financial maintained a Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) the same day, without assigning a price target.
In addition to Asthika Goonewardene, Citi’s Yigal Nochomovitz also expressed bullish sentiments for Summit Therapeutics Inc. (NASDAQ:SMMT) in a report released on September 24, assigning the stock a Buy rating with a $35 price target.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that specializes in creating novel medications for infectious and cancerous diseases.
While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.